Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

CRC proteomic analysis by LC MS/MS

ABSTRACT: analysis of fecal samples in colorectal cancer Egyptians patients

INSTRUMENT(S): Q Exactive HF

ORGANISM(S): Human Gut Metagenome

DISEASE(S): Colon Cancer

SUBMITTER: rana abo-hammam

LAB HEAD: Rana Hashem

PROVIDER: PXD037271 | Pride | 2023-08-18

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	21P04220001.mzML	Mzml
	21P04220001.raw	Raw
	21P04220002.mzML	Mzml
	21P04220002.raw	Raw
	21P04220004.mzML	Mzml

Items per page:

1 - 5 of 16

Similar Datasets

Leaf-cutting ant feces LC-MS/MS

Project description:Leaf-cutting ants of the genera Acromyrmex and Atta live in mutualistic symbiosis with a basidiomycete fungus (Leucocoprinus gongylophorus), which they cultivate as fungal gardens in underground nest chambers. The ants provide the fungus with a growth substrate consisting of freshly cut leaf fragments. After new leaf fragments are brought into the nest, the ants chew them into smaller pieces and apply droplets of fecal fluid to the leaf pulp before depositing this mixed substrate in the fungus garden and inoculating it with small tufts of mycelium from older parts of the garden. Previous work has shown that the fecal fluid contains a range of digestive enzymes including proteases, amylases, chitinases, cellulases, pectinases, hemicellulases and laccases, and that most of these enzymes are produced by the fungal symbiont in specialized structures called gongylidia that the ants eat. After ingestion, the enzymes apparently pass unharmed through the alimentary channel of the ants and end up in the fecal fluid. Most likely this complex system is an adaptation of the ant-fungus symbiosis to a herbivorous lifestyle, as the ancient ancestors of the ants and the fungus lived as hunter-gatherers and saprotrophs, respectively. The promise of fecal fluid for getting insight into the molecular adaptations that enables the ant-fungus holosymbiont to live as a herbivore, led us to investigate the fecal fluid proteome using LC-MS/MS in order to get a more comprehensive picture of the repertoire of proteins present.

2021-01-12 | PXD016395 | Pride

Impact of fecal microbiota transplantation (FMT) in 3 days-ABX-treated recipient mice using feces from 6 NSCLC patients at diagnosis.

Project description:This study aimed to analyze changes in gut microbiota composition in mice after transplantation of fecal microbiota (FMT, N = 6) from the feces of NSCLC patients by analyzing fecal content using 16S rRNA sequencing, 10 days after transplantation. Specific-pathogen-free (SPF) mice were used for each experiments (N=4) as controls.

2023-07-01 | E-MTAB-12812 | biostudies-arrayexpress

Effect of morphine treatment on microbiome in the context of microbial transplant.

Project description:Morphine causes microbial dysbiosis. In this study we focused on restoration of native microbiota in morphine treated mice and looked at the extent of restoration and immunological consequences of this restoration. Fecal transplant has been successfully used clinically, especially for treating C. difficile infection2528. With our expanding knowledge of the central role of microbiome in maintenance of host immune homeostasis17, fecal transplant is gaining importance as a therapy for indications resulting from microbial dysbiosis. There is a major difference between fecal transplant being used for the treatment of C. difficile infection and the conditions described in our studies. The former strategy is based on the argument that microbial dysbiosis caused by disproportionate overgrowth of a pathobiont can be out-competed by re-introducing the missing flora by way of a normal microbiome transplant. This strategy is independent of host factors and systemic effects on the microbial composition. Here, we show that microbial dysbiosis caused due to morphine can be reversed by transplantation of microbiota from the placebo-treated animals.

2016-06-01 | E-MTAB-3723 | biostudies-arrayexpress

Disease Severity and Immune Activity Relate to Inter-Kingdom Gut Microbiome States in Ethnically Distinct Ulcerative Colitis Patients

Project description:Significant gut microbiota heterogeneity exists amongst UC patients though the clinical implications of this variance are unknown. European and South Asian UC patients exhibit distinct disease risk alleles, many of which regulate immune function and relate to variation in gut microbiota Î²-diversity. We hypothesized ethnically distinct UC patients exhibit discrete gut microbiotas with unique luminal metabolic programming that influence adaptive immune responses and relate to clinical status. Using parallel bacterial 16S rRNA and fungal ITS2 sequencing of fecal samples (UC n=30; healthy n=13), we corroborated previous observations of UC-associated depletion of bacterial diversity and demonstrated significant gastrointestinal expansion of Saccharomycetales as a novel UC characteristic. We identified four distinct microbial community states (MCS 1-4), confirmed their existence using microbiota data from an independent UC cohort, and show they co-associate with patient ethnicity and degree of disease severity. Each MCS was predicted to be uniquely enriched for specific amino acid, carbohydrate, and lipid metabolism pathways and exhibited significant luminal enrichment of metabolic products from these pathways. Using a novel in vitro human DC/T-cell assay we show that DC exposure to patient fecal water led to MCS -specific changes in T-cell populations, particularly the Th1:Th2 ratio, and that patients with the most severe disease exhibited the greatest Th2 skewing. Thus, based on ethnicity, microbiome composition, and associated metabolic dysfunction, UC patients may be stratified in a clinically and immunologically meaningful manner, providing a platform for the development of FMC-focused therapy. Fecal microbiome was assessed with Affymetrix PhyloChip arrays from patients with ulcerative colitis and healthy controls.

2016-07-25 | E-GEOD-78724 | biostudies-arrayexpress

ASTRAL deep-proteotyping of a human fecal standard to evaluate metaproteomics strategies.

Project description:Metaproteomics of a human fecal standard, MetaP, with ASTRAL tandem mass spectometer operated in data-dependent analysis for deep-proteotyping and evaluate metaproteomics strategies.

2024-03-07 | PXD045838 | Pride

Exploris 480 dataset acquired on a human fecal standard to evaluate metaproteomics strategies.

Project description:Metaproteomics of a human fecal standard, MetaP, with an Exploris480 tandem mass spectometer operated in data-dependent analysis for proteotyping and evaluation of metaproteomics strategies.

2024-03-07 | PXD047139 | Pride

ASTRAL 60 and 90 min in-depth metaproteomics of a human fecal standard to evaluate depth of analysis following a taxonomical proteotyping strategy.

Project description:In-depth metaproteomics of a human fecal standard, MetaP, with ASTRAL tandem mass spectometer operated in data-independent acquisition mode for 60 min or 90 min and with a database built following sample taxonomical proteotyping.

2024-03-07 | PXD046320 | Pride

ASTRAL 15 and 30 min in-depth metaproteomics of a human fecal standard to evaluate depth of analysis following a taxonomical proteotyping strategy.

Project description:In-depth metaproteomics of a human fecal standard, MetaP, with ASTRAL tandem mass spectometer operated in data-independent acquisition mode for 15 min or 30 min and with a database built following sample taxonomical proteotyping.

2024-03-07 | PXD046290 | Pride

Gut microbiota composition after 12 weeks of home based lifestyle intervention in breast cancer survivors (MOVIS)

Project description:Analysis of breast cancer survivors' gut microbiota after lifestyle intervention, during the COVID-19 lockdown, by 16S sequencing of fecal samples.

2023-01-13 | E-MTAB-12486 | biostudies-arrayexpress

Mouse Fecal Metaproteomics - DIA

Project description:Evaluates the impact of fecal sample preparation, protein digestion, data acquisition mode and bioinformatic workflow on metaproteomic observations

2024-07-03 | PXD049089 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data